• 1
    Weis M, von SW. Cardiac allograft vasculopathy: A review. Circulation 1997; 96: 20692077.
  • 2
    Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009. J Heart Lung Transplant 2009; 28: 10071022.
  • 3
    Vassalli G, Gallino A, Weis M, et al. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 2003; 24: 11801188.
  • 4
    Valantine HA. Cardiac allograft vasculopathy: Central role of endothelial injury leading to transplant “atheroma.” Transplantation 2003; 76: 891899.
  • 5
    Schmauss D, Weis M. Cardiac allograft vasculopathy: Recent developments. Circulation 2008; 117: 21312141.
  • 6
    Moon JI, Kim YS, Kim MS, et al. Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: In vitro study. Transplant Proc 2000; 32: 20262027.
  • 7
    Xiao F, Chong A, Shen J, et al. Pharmacologically induced regression of chronic transplant rejection. Transplantation 1995; 60: 10651072.
  • 8
    Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847858.
  • 9
    Arora S, Ueland T, Wennerblom B, et al. Effect of everolimus introduction on cardiac allograft vasculopathy—results of a randomized, multicenter trial. Transplantation 2011; 92: 235243.
  • 10
    Chen WQ, Zhong L, Zhang L, et al. Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol 2009; 156: 941951.
  • 11
    Sarno G, Onuma Y, Garcia Garcia HM, et al. IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. Catheter Cardiovasc Interv 2010; 75: 914918.
  • 12
    Nasu K, Tsuchikane E, Katoh O, et al. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology ` with in vitro histopathology. J Am Coll Cardiol 2006; 47: 24052412.
  • 13
    Nair A, Margolis M, Kuban B, Vince DG. Automated coronary plaque characterisation with intravascular ultrasound backscatter: Ex vivo validation. EuroIntervention 2007; 3: 113120.
  • 14
    Calvert PA, Obaid DR, O'Sullivan M, et al. Association between IVUS findings and adverse outcomes in patients with coronary artery disease: The VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. JACC Cardiovasc Imaging 2011; 4: 894901.
  • 15
    Marso SP, Frutkin AD, Mehta SK, et al. Intravascular ultrasound measures of coronary atherosclerosis are associated with the Framingham risk score: An analysis from a global IVUS registry. EuroIntervention 2009; 5: 212218.
  • 16
    Gullestad L, Iversen M, Mortensen SA, et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: A multicenter, randomized trial. Transplantation 2010; 89: 864872.
  • 17
    Mintz GS, Nissen SE, Anderson WD, et al. American college of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001; 37: 14781492.
  • 18
    Bollerslev J, Ueland T, Jorgensen AP, et al. Positive effects of a physiological dose of GH on markers of atherogenesis: A placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 2006; 154: 537543.
  • 19
    Arora S, Gullestad L, Wergeland R, et al. Probrain natriuretic peptide and C-reactive protein as markers of acute rejection, allograft vasculopathy, and mortality in heart transplantation. Transplantation 2007; 83: 13081315.
  • 20
    Nair A, Kuban BD, Tuzcu EM Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002; 106: 22002206.
  • 21
    Raichlin E, Bae JH, Kushwaha SS, et al. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol 2009; 53: 12791286.
  • 22
    Raichlin E, Kushwaha SS. Proliferation signal inhibitors and cardiac allograft vasculopathy. Curr Opin Organ Transplant 2008; 13: 543550.
  • 23
    Eisen H. Long-term cardiovascular risk in transplantation—insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant 2006; 21(Suppl 3): iii9iii13.
  • 24
    Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847858.
  • 25
    Mehra MR, Uber PA. TOR inhibitors and cardiac allograft vasculopathy: Is inhibition of intimal thickening an adequate surrogate of benefit? J Heart Lung Transplant 2003; 22: 501504.
  • 26
    Delgado JF, Manito N, Segovia J, et al. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. Transplant Rev 2009; 23: 6979.
  • 27
    Johnson DE, Gao SZ, Schroeder JS, DeCampli WM, Billingham ME. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant 1989; 8: 349359.
  • 28
    Valantine HA. Cardiac allograft vasculopathy: Central role of endothelial injury leading to transplant “atheroma.” Transplantation 2003; 76: 891899.
  • 29
    Day JD, Rayburn BK, Gaudin PB, et al. Cardiac allograft vasculopathy: The central pathogenetic role of ischemia-induced endothelial cell injury. J Heart Lung Transplant 1995; 14: S142S149.
  • 30
    Arora S, Gunther A, Wennerblom B, et al. Systemic markers of inflammation are associated with cardiac allograft vasculopathy and an increased intimal inflammatory component. Am J Transplant 2010; 10: 14281436.
  • 31
    Hernandez JM, de Prada JA, Burgos V, et al. Virtual histology intravascular ultrasound assessment of cardiac allograft vasculopathy from 1 to 20 years after heart transplantation. J Heart Lung Transplant 2009; 28: 156162.
  • 32
    Klauss V, Ackermann K, Spes CH, et al. Coronary plaque morphologic characteristics early and late after heart transplantation: In vivo analysis with intravascular ultrasonography. Am Heart J 1997; 133: 2935.
  • 33
    Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 22922301.
  • 34
    Corti R, Hutter R, Badimon JJ, Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis 2004; 17: 3544.
  • 35
    Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006; 4: 11861193.
  • 36
    Martinez-Dolz L, Almenar L, Reganon E, et al. Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy. J Heart Lung Transplant 2008; 27: 760766.
  • 37
    Lehle K, Schreml S, Kunz-Schughart LA, et al. mTOR inhibitors and calcineurin inhibitors do not affect adhesion molecule expression of human macro- and microvascular endothelial cells. J Vasc Res 2008; 45: 333342.
  • 38
    Manito N, Delgado JF, Crespo-Leiro MG, et al. Clinical recommendations for the use of everolimus in heart transplantation. Transplant Rev 2010; 24: 129142.